Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
Profile & Fundamentals
Review the profile, reported financial history, AI financial assessment, dividends, splits, and dated events for Natera.
Profile & Fundamentals
Natera Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in Januar
Company profile record
Natera Inc
Common Stock · Healthcare · Diagnostics & Research
Company
- Company / asset
- Natera Inc
- Security type
- Common Stock
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- HQ
- 🇺🇸 United States
- Head office
- 13011 McCallen Pass, Austin, TX, United States, 78753
Leadership & scale
- Chief executive
- Mr. Steven Leonard Chapman
- CEO year born
- 1979
- Full-time employees
- 6.1K
- Fiscal year end
- December
- IPO date
- 2015-07-02
Fundamentals snapshot
- Market Cap
- USD 37.9B
- P/E
- --
- Revenue (Q1 26)
- USD 696.6M
- Profit (Q1 26)
- USD -85.1M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 2.3B
- Shares in public float
- 139.1M
- Insider ownership
- 2.98%
Reporting & identifiers
- Symbol
- NTRA.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US6323071042
- Asset ID
- equity_9bcb5738-6092-5a90-83b0-28f2be8172b2
Ownership
Shares Outstanding
Latest: 141.5M | Max: 141.5M | Min: 4.3M
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open every chart, financial statement, event, and source table.